https://docs.publicnow.com/viewDoc?hash_primary=AC426F68EE52C546C7C2D1295786BC2CED9B2BA4
Ipsen To Acquire Albireo For $42.00/Share Plus A Contingent Value Right Of $10.00/Share
Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.